Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 09, 2024

Crovalimab vs Eculizumab for Complement Inhibition–Naïve Paroxysmal Nocturnal Hemoglobinuria

American Journal of Hematology


Additional Info

American Journal of Hematology
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Am. J. Hematol 2024 Jun 17;[EPub Ahead of Print], A Röth, G He, H Tong, Z Lin, X Wang, C Chai-Adisaksopha, JH Lee, A Brodsky, C Hantaweepant, TE Dumagay, R Demichelis-Gómez, P Rojnuckarin, J Sun, M Höglund, JH Jang, A Gaya, F Silva, N Obara, RJ Kelly, L Beveridge, S Buatois, S Chebon, B Gentile, P Lundberg, S Sreckovic, JI Nishimura, A Risitano, B Han

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading